Introduction
The increased prevalence of obesity and type 2 diabetes, with the attendant increase in morbidity and mortality, pose a substantial therapeutic challenge. Type 2 diabetes is a complex polygenic disease with a strong genetic component, as indicated by the high prevalence in certain ethnic groups and by studies of identical twins. Nevertheless, the rapid increase in the prevalence of obesity-associated disease conditions, including type 2 diabetes, in worldwide populations suggests the contribution of environmental factors. A widely accepted explanation lays on the frequent consumption of processed foods with a high-calorie content and the reduction in physical exercise due to sedentary lifestyle in modern urban environment. Disruption of energy balance has led to an increased prevalence of these conditions ( ). Type 2 diabetes is characterized by altered lipid and glucose metabolism (fasting or postprandial 1 hyperglycemia, dyslipidemia) as a consequence of combined insulin resistance in skeletal muscle, liver and adipose tissue and relative defects of insulin secretion by -cells that may arise due to an imbalance between energy intake and expenditure ( ). Insulin resistance β 2 occurs when a normal dose of hormone is unable to elicit its metabolic responses. Insulin is the primary anabolic hormone that stimulates uptake and storage of fuel substrates, while inhibiting substrate production in peripheral tissues. It lowers blood glucose levels by facilitating glucose uptake, mainly into skeletal muscle and fat tissue, and by inhibiting endogenous glucose production in the liver.
Peripheral insulin resistance is associated with lipid partitioning in specific compartments, i.e. muscle and liver, more than with obesity per . Usually, after an asymptomatic period of insulin resistance, hyperglycemia appears when pancreatic -cells fail to secrete sufficient se β amounts of insulin to meet the metabolic demand. In the natural history of type 2 diabetes, pancreatic -cells initially compensate for β insulin resistance by hypersecretion of insulin, but with time, progressive -cell failure leads to insulindeficiency and hyperglycemia
In addition, performed activity can improve lipid profile, decrease body weight and percentage of body fat, lower blood pressure, positively affect thromboembolic state and thus reduce overall cardiovascular disease risk ( , ). These beneficial effects are partly 8 9 explained by AMPK activation during physical activity not only in skeletal muscle but also in liver and adipose tissue ( ). Indeed, in 10 type 2 diabetes patients, improvement in glycemic control during physical activity is linked to enhanced glucose transport in skeletal muscle and reduction in hepatic glucose production ( ). Interestingly, these effects are insulin-independent. This probably explains that, 11
despite whole-body insulin resistance, AMPK can be fully activated by physical training in type 2 diabetes patients as compared to healthy controls ( ). In addition to this acute metabolic effect on glucose disposal, repeated physical activity improves insulin action in skeletal 12
muscle from obese and insulin-resistant individuals ( ). This improvement parallels an increase in the oxidative capacity of skeletal 13 muscle by up-regulating lipid oxidation and the expression of proteins involved in mitochondrial biogenesis. Both of these mechanisms are linked to AMPK activation that seems to be a crucial key for metabolic adaptation to physical activity (see below). Use of AMPK agonists could be a new strategy to increased endurance without exercise in physically inactive type 2 diabetes patients.
Management of -cell mass and function in type 2 diabetes
β Clinical studies demonstrated that TZDs improve -cell function for a long time both as monotherapy and in combination with β metformin or sulfonylurea ( ). They may also improve insulin processing, as demonstrated by a reduction in the proinsulin/total 14 immunoreactive insulin ratio, (an indicator of -cell dysfunction) whereas sulfonylureas did not ( adiponectin has protective effect on endothelial functions and CVD and type 2 diabetes mellitus are associated with low plasma concentration of adiponectin ( ). In isolated rat hearts, adiponectin protects from myocardial contractile dysfunction and limits infarct 24 size in following ischaemia and reperfusion by a mechanism involving activation of AMPK and production of NO ( ). In humans, 25
clinical trials concerning use of recombinant adiponectin during myocardial infarction are not available. Nevertheless, the increase of blood adiponectin levels to normal range after a cardiovascular event could be a new therapeutic target. To this aim, the association of drugs classically used for the prevention of recurrence of CVD and some dietary modifications could be useful to restore adiponectin levels in the normal range. This has been described recently in a double-blind, placebo-controlled, parallel trial where 44 patients who survived myocardial infarction and received statin therapy for at least 6 months were randomised to receive either 3 85 mg/day of × chokeberry flavonoid extract or placebo for a period of 6 weeks ( ). A significant increase in adiponectin levels and also a reduction in 26 inflammatory markers were found when flavanoid extract was used. These beneficial effects, regardless of statins, are potentially interesting for secondary prevention of ischaemic heart disease.
Structure and regulation of AMPK
AMP-activated protein kinase (AMPK) plays an important role in the regulation of cellular and whole-body energy homeostasis.
AMPK has been described as a metabolic master switch that mediates the cellular adaptation to nutritional and environmental variations " " depleting intracellular ATP levels, including heat shock, hypoxia, starvation or prolonged exercise. Regardless, the result of AMPK activation is the inhibition of energy-consuming biosynthetic pathways (such as fatty acid synthesis in liver and adipocytes, cholesterol synthesis in liver, protein synthesis in liver and muscle and insulin secretion from -cell) and the activation of ATP-producing catabolic β pathways (such as fatty acid uptake and oxidation in multiple tissue, glycolysis in heart and mitochondrial biogenesis in muscle). AMPK can also modulate transcription of specific genes involved in energy metabolism, thereby exerting long-term metabolic control.
AMPK is composed of three different subunits , and . Homologues of these subunits have been identified in mammals, genes also give rise to short and long splice variants adding to the diversity. Differences in level expression and tissue distribution of the three subunits types were also described. The catalytic 1 subunit is strongly expressed in the kidney, the lung and the adipose tissue, α whereas catalytic 2 subunit is predominantly found in heart and skeletal muscles. The regulatory 1 subunit is preferentially expressed in α β the liver and 2 in the skeletal muscle. The regulatory 1 and 2 subunits have broad tissue distribution whereas 3 seems highly specific The catalytic domain has a site of phosphorylation at threonine residue Thr172 within the activation loop (T-loop) which is the key site for AMPK activation by upstream kinases ( , ). In the extreme C-terminus part, a region of ~150 amino acid residues is required for 30 31 association with and subunits, whereas the central part seems to have an inhibitory function ( , ). Moreover, localization of 
Mimicking the beneficial effects of physical exercise
Although appropriate diet and exercise regimes should therefore be the first choice of treatment and prevention of type 2 diabetes, there are patient groups for whom such regimes are not appropriate for other medical reasons, or where compliance is difficult because of social factors or poor motivation. In these cases, drugs acting on the signaling pathways that induce the favourable changes in whole body metabolism are attractive candidates for treatment and prevention. It is now well established that muscle contraction is a prototypical activators in animal models of type 2 diabetes have provided promising results. The first evidence came from treatment with the in vivo pharmacological compound AICAR of various animal models of insulin resistance, causing improvement in most, if not all, the metabolic disturbances of these animals ( ). Interestingly, long-term AICAR administration prevents the development of hyperglycemia in 63 -67 Zucker diabetic fatty (ZDF) rats, improves peripheral insulin sensitivity in skeletal muscle and delays -cell dysfunction associated with β type 2 diabetes ( ). In addition, ablation of AMPK 2 specifically in skeletal muscle, exacerbates the development of insulin resistance 66 α and glucose intolerance caused by high-fat feeding ( ). Finally, it was reported that the insulin sensitizing effects of AICAR were 68
diminished by inhibition of AMPK in C2C12 myotubes ( ). Repetitive pharmacological activation of AMPK results in 69 in vivo expression of specific muscle proteins mimicking some of the effects of exercise training such as increased glucose uptake and mitochondrial biogenesis ( ). In rodent, AICAR or chronic intake of the creatine analogue -guanidinopropionic acid ( -GPA) Figure 3 β β increases the expression of genes encoding glucose transporter GLUT4, hexokinase II and markers of mitochondrial biogenesis ( ). 70 -73 A recent report reveals that peroxisome proliferator-activated receptor-coactivator-1 (PGC-1 ) expression is required for metformin treatment of subjects with type 2 diabetes significantly increases AMPK activity in skeletal muscle and this stimulation is accompanied by enhanced peripheral glucose disposal ( , ). Metformin is also able to restore glucose uptake stimulation in 79 80 insulin-resistant cardiomyocytes, suggesting that AMPK activation could be a potential therapeutic approach to treat insulin resistance in diabetic hearts ( ). Finally, activation of AMPK in response to physical exercise is also observed in extra-muscular tissues such as liver 81 and adipose tissue and might account for additional metabolic benefits ( ). 10
Mimicking the beneficial effects of calorie/dietary restriction
Calorie intake is an important determinant of health. Excessive calorie intake and subsequent abdominal obesity increase the risk of developing chronic disease such as type 2 diabetes, cardiovascular complications and premature mortality. In overweight and obese humans, calorie restriction (CR) with adequate nutrition improves glucose tolerance and insulin action and reduces mortality for type 2 diabetes and cardiovascular diseases ( ). Even if calorie restriction produces a metabolic profile desirable for treating type 2 82 -85 diabetes, it is unlikely that such restriction will be widely adopted because of the difficulty in maintaining long-term low calorie intake in modern society. There is an increased interest in developing pharmacological agents acting as calorie-restriction mimetics. Such agents Furthermore, it has been demonstrated that SIRT1 functions as an upstream regulator of the LKB1/AMPK signaling axis in response to RSV activation in hepatocytes ( ). SIRT1 promotes LKB1-dependent AMPK stimulation through the direct deacetylation and activation 98 of LKB1 ( ). It should be noted that the regulation of LKB1/AMPK signaling by SIRT1 is probably tissue-specific as 53 resveratrol-stimulated AMPK activation is independent of SIRT1 in neurons ( ). This is consistent with data suggesting that 99 in vivo resveratrol may act on additional sirtuins than SIRT1 or on different targets ( ). Nevertheless, understanding the role of AMPK in the 92 action of polyphenols will provide valuable information to aid decisions about whether these compounds might be used as additives in foods or beverages to promote health and attenuate, or delay, the onset of various diseases, including cardiovascular disease and diabetes.
Role of AMPK in the control of glucose homeostasis
Glucose homeostasis is maintained by a balance between glucose production and glucose uptake by peripheral tissues. Elevated hepatic glucose production (HGP) is a major cause of fasting hyperglycemia in diabetic subjects ( ). The importance of AMPK in the 2 control of glucose output by the liver is emphasized by findings showing that pharmacological activation of AMPK leads to inhibition of HGP and . It has been first shown that systemic infusion of AICAR in normal and insulin-resistant obese rats led to the in vitro in vivo inhibition of hepatic glucose production (HGP) ( ). Similarly, it was reported that AMPK activation by metformin in cultured rat 63
hepatocytes mediates the inhibitory effects of the drug on hepatic glucose production ( ). There is now good evidence from 100 in vivo studies of mice deficient in the upstream kinase LKB1 in the liver that the blood-lowering effect of metformin is mediated by activation of the LKB1/AMPK axis ( ). It has been also reported that short-term hepatic expression of a constitutively active form of the 2 catalytic 101 gluconeogenesis by AMPK is achieved at least to a large extent the regulation of a transcriptional coactivator, transducer of regulated via CREB activity 2 (TORC2) ( ). TORC2 mediates CREB-dependent transcription of PGC1 and its subsequent gluconeogenic targets 105 α PEPCK and G6Pase. TORC2 is regulated by multiple signaling pathways in response to changes in glucagon and insulin levels or intracellular energy status. AMPK activation causes TORC2 phosphorylation and sequesters the coactivator in the cytoplasm, thus blunting the expression of the gluconeogenic program ( ). A physiological link has been established between the potent effects of Figure 4 various circulating adipocyte-derived hormones circulating levels and hepatic AMPK activity in the maintenance of blood glucose levels.
Low blood glucose levels and reduced HGP in mice lacking resistin are likely related, at least in part, to activation of AMPK and decreased expression of gluconeogenic enzymes in the liver ( ). Administration of adiponectin is known to reduce both blood glucose 106 levels and expression of gluconeogenic genes. It has been shown that these effects required AMPK activation at least in the liver ( ). 107
According to this result, adiponectin failed to regulate HGP in liver-specific AMPK 2 KO mice ( ).
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Skeletal muscle is the main site for glucose disposal in the body. Insulin increases glucose uptake in the muscle by stimulating the translocation of glucose transporter GLUT4 from intracellular vesicles to the cell surface. ( ). It has been shown that muscular Figure 3 AMPK activation stimulates muscle glucose uptake either by exercise or by AICAR and this occurs through a distinct mechanism than the insulin-signaling pathway. AICAR can effectively increase glucose transport and GLUT4 translocation in skeletal muscle, not only in lean subjects but also in type 2 diabetes subjects (
). An AMPK-dependant increase in glucose transport is therefore observed in 109 insulin-resistant skeletal muscle, both in rodents and humans, providing evidence that the AMPK pathway can be activated in this case (46 ) . Stimulation of AMPK in the muscle could be an efficient method to increase glucose uptake in an insulin-independent manner, thus bypassing defective insulin signaling, such as one observed in type 2 diabetes patients. Although the upstream stimuli that activate AMPK are relatively well known ( ), the signaling mechanisms downstream of AMPK which regulate muscle glucose transport are not so well 46
understood. It has been recently discovered that the Akt substrate of 160kDa (AS160/TBC1D4), downstream target of Akt, played a major role in regulating insulin-stimulated glucose uptake. Another possible downstream effector of AMPK in the regulation of muscle glucose transport is an AS160/TBC1D4 homolog, TBC1D1 ( ). AS160/TBC1D4 is a Rab-GTPase activating protein that regulates the 110 translocation of GLUT4 from intracellular vesicles to the plasma membrane by maintaining small G-proteins, known as Rab, in a GDP-bound state. The phosphorylation of AS160 at specific sites is thought to disrupt GTPase activity and allow the release of AS160 inhibition on GLUT4 vesicle intracellular localization, thus initializing the vesicle translocation ( ). TBC1D1 is also a Rab-GTPase 110 activating protein and its phosphorylation is enhanced in mouse skeletal muscle myotubes following treatment with AICAR ( ). In a 111 similar way, exercise and AICAR-induced AMPK activation caused AS160/TBC1D4 phosphorylation in skeletal muscle like insulin ( ). 28
Furthermore, AS160 phosphorylation as well as glucose uptake is increased in skeletal muscle following a resistance exercise in humans.
A positive correlation between increased AS160/TBC1D4 phosphorylation and muscle glucose uptake during post-exercise recovery has been observed, as well as increased muscle AMPK 2 activity ( ). Taken together, these results show that AMPK-induced muscle
glucose uptake stimulation is mediated by AS160/TBC1D4. This represents a point of convergence connecting insulin, contraction and AMPK-stimulated glucose transport. It has been observed that exercise-induced AMPK activation in muscle is diminished in both obese non-diabetic and obese type 2 diabetes subjects, but maintained in lean type 2 diabetes patients ( , ). This suggests that dysregulation 12 113 of the AMPK pathway may be more associated with obesity rather than with type 2 diabetes . This reflects impaired adaptability to per se utilize lipid and carbohydrate fuels and to transition between them, also referred as metabolic inflexibility ( ), observed in obese and 114 insulin resistant people. It is therefore likely that obese patients may require a more intense exercise protocol to achieve the same benefits than in lean individuals ( ). Consistently, in obese type 2 diabetes subjects, AS160 phosphorylation is blunted in skeletal muscle 113 following moderate intensity exercise ( ). 113 Several cytokines have been shown to stimulate glucose transport in muscle in an AMPK-dependent manner. Leptin is an adipokine recently shown to improve insulin action in muscle of patients with lipodystrophy, although the role of AMPK activation as mediator is not studied ( ). Leptin is also known to stimulate glucose uptake in peripheral tissue ( , ). It has been shown that leptin 115 116 117 selectively stimulated AMPK 2 phosphorylation and activation in skeletal muscle, further confirming the role of AMPK in α leptin-mediated stimulation of glucose transport ( ). Adiponectin also increases glucose transport in both lean and obese skeletal 118 muscle, although the effect is less significant in the latter ( ). This suggests a possible development of adiponectin resistance related to 119 metabolic inflexibility observed in skeletal muscle from obese individuals. Interleukin-6 (IL-6) is a proinflammatory cytokine that activates AMPK and is thought to modify insulin sensitivity. Recently, it has also been recognized as a myokine , due to its release from " " the skeletal muscle during prolonged exercise ( ). Muscle strips obtained from healthy young men treated with IL-6 show an increased 120 glucose uptake concomitant with AMPK phosphorylation ( ). It has been shown that IL-6-stimulated glucose transport is mediated 121 via the LKB1/AMPK/AS160 pathway. However, the same study also shows that IL-6 has a dual effect: short term IL-6 treatment is additive to insulin on activating glucose transport and AS160 phosphorylation, resulting in an improved glucose tolerance and insulin sensitivity in mice, whereas chronic exposure produces insulin resistance both and ( ). It has been shown that AMPK participates in in vitro in vivo 122 the regulation of IL-6 release from oxidative muscle. It has been also suggested that AICAR, in addition to activating AMPK, suppresses IL-6 release by an AMPK independent mechanism ( ). Collectively these results demonstrate that AMPK plays a major role in glucose 123 homeostasis by modulating glucose transport in skeletal muscle. Thus, AMPK could have a significant role in the modification of glucose muscle metabolism, thus establishing the AMPK pathway as an attractive target for the treatment of type 2 diabetes.
Role of AMPK in the control of lipid metabolism
Both insulin resistance and type 2 diabetes are characterized by dyslipidemia, which is an important and common risk factor for cardiovascular disease. Diabetic dyslipidemia is a cluster of potentially atherogenic lipid and lipoprotein abnormalities that are metabolically interrelated. AMPK coordinates the changes in the hepatic lipid metabolism and, so, regulates the partitioning of fatty acids between oxidative and biosynthetic pathways. Thus, once activated, AMPK phosphorylates and inactivates a number of metabolic enzymes involved in ATP-consuming cellular events, such as 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) and acetyl-CoA carboxylase (ACC), key enzymes in hepatic cholesterol and fatty acid synthesis ( ). In addition, AMPK suppresses Figure 4 expression of lipogenesis-associated genes such as fatty acid synthase, pyruvate kinase and ACC ( , ). ACC is an important 102 124 -127 rate-controlling enzyme for the synthesis of malonyl-CoA, which is both a critical precursor for the biosynthesis of fatty acids and a potent
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Front Biosci . Author manuscript Page / 7 15 inhibitor of mitochondrial fatty acid oxidation. Inhibition of ACC by AMPK leads to a drop in malonyl-CoA content and a subsequent decrease in fatty acid synthesis and increase in fatty acid oxidation, thus reducing excessive storage of triglycerides. Malonyl CoA decarboxylase (MCD), an enzyme involved in the turnover of malonyl-CoA, has been shown to be activated by AMPK in response to energy depletion, resulting in reduced malonyl CoA levels and increased fatty acid oxidation ( ). Consistently, overexpression of 128 AMPK 2-CA in the liver, treatment with AICAR or metformin in lean and obese rodents increase plasma -hydroxybutyrate levels, α β suggesting elevated hepatic lipid oxidation, concomitantly with a decrease in plasma triglyceride levels ( , , ). Conversely, 63 100 102 liver-specific AMPK 2 deletion leads to increased plasma triglyceride levels and enhances hepatic lipogenesis ( ). These data α 108 emphasizes the critical role for AMPK in the control of hepatic lipid deposition decreased lipogenesis and increased lipid oxidation, via thus improving lipid profile in type 2 diabetes. In addition, AMPK also emerged as a key player in the regulation of fatty acid oxidation in skeletal muscle ( ). In rodent skeletal muscle, stimulation of AMPK by AICAR increased the oxidation of palmitate ( , ). Figure 3 129 130
Leptin, an adipocyte-secreted hormone that plays a pivotal role in regulation of energy expenditure, was found to increase fatty acid oxidation in skeletal muscle by activating AMPK ( ). Leptin activates AMPK by a dual effect, i.e. early and transient activation of 118 AMPK by leptin directly at the level of muscle and a more sustained activation mediated through the hypothalamic-sympathetic nervous system axis and adrenergic receptors in muscle (
). Mice harboring a gain-of-function of the 3 subunit (R225Q) in skeletal muscle
α-118 γ demonstrate lower intramuscular TG content, increased lipid oxidation and protection against diet-induced insulin resistance ( ). As in 131 the liver, AMPK enhances fatty acid oxidation by inactivating ACC, thereby reducing the synthesis of malonyl CoA. However, recent studies using mAMPK-KD mice indicate that AMPK-independent pathways can regulate skeletal muscle fatty acid oxidation ( ). 132
Furthermore, incubation of isolated rat muscle with both AICAR and electrical stimulation result in higher fatty acid oxidation than for each condition alone ( ). In human skeletal muscle, the connection between changes in AMPK activation and fatty acid oxidation 133 during exercise is not clear ( , ). 134 135
Management of fatty liver disease by AMPK activation
One of the critical complications of type 2 diabetes is nonalcoholic fatty liver disease (NAFDL), a disorder of triacylglycerol accumulation in the liver that has potential to develop into end stage liver failure. It has been proposed that steatosis primed the liver to progress to more severe liver pathologies when individuals were exposed to subsequent metabolic and/or environmental stresses. Insulin resistance is a major feature of NAFDL and studies in humans and various animal models suggest that efforts to enhance insulin sensitivity might improve fatty liver disease. The efficacy of insulin-sensitizer metformin as a treatment for this disease is confirmed in obese ob/ob mice, which develop hyperinsulinemia, insulin resistance and fatty livers ( ). Similarly, adiponectin treatment restores insulin 136 sensitivity and decreases hepatic steatosis by lowering the triglyceride content in the liver of obese mice ( ). Metabolic improvement of 137 adiponectin is linked to an activation of AMPK in the liver that decreases fatty acid biosynthesis and increases mitochondrial fatty acids
oxidation (
). This is confirmed by a decrease in liver triglycerides content in lean and obese rodents during AICAR infusion ( ) and Thus, inhibition rather than activation of AMPK would be desirable for the treatment of type 2 diabetes in order to reverse the decline in glucose-induced insulin secretion. Surprinsingly, it has been reported that agents that suppress insulin secretion, such as diazoxide, improve glucose tolerance and -cell function (
). This effect is thought to be mediated hyperpolarization of -cells, thereby 
Management of cardiovascular diseases by AMPK activation
Type 2 diabetes is associated with an increased risk of cardiovascular disease and coronary heart disease mortality. The high energy demands of the heart are primarily met by the metabolism of fatty acids and glucose, both processes being regulated by AMPK. Indeed, AMPK stimulates glycolysis and sustains energy supply during ischemic stress. Promotion of glucose oxidation or inhibition of fatty acid oxidation in ischemic/reperfused hearts could be a promising novel therapeutic approach to myocardial ischemic conditions. Such a mechanism has been demonstrated during the phenomenon called ischemic preconditioning. Brief episodes of myocardial ischemia render the heart more resistant to subsequent ischemic episodes ( ). Ischemic preconditioning is known to induce endogenous protective 165 mechanisms in the heart. It activates AMPK in a PKC-dependent manner and promotes glucose utilization in myocardial cells, supporting resistance toward ischemic consequences ( ). Thus, AMPK activators could be of particular interest for the management of myocardial 166 ischemia. Attractively, it has been reported that adiponectin protects the heart from ischemia by activating AMPK and increasing the energy supply to heart cells ( ). In addition, it has also been reported that adiponectin attenuates cardiac hypertrophy through activation 167 of AMPK signaling pathway ( , ). 168 169 The presence of endothelial cell dysfunction in patients with type 2 diabetes, as manifested by impaired vascular relaxation or increase in circulating vascular cell adhesion molecules is thought to be one component of the inflammatory process initiating atherogenesis. In this respect, metformin has been proposed to improve endothelium function in diabetes by favoring phosphorylation of endothelial NO 
Conclusion and medical perspectives
Because of its global favourable effects on energy metabolism pathways, it is tempting to consider AMPK as a potential therapeutic target in the prevention and the treatment of type 2 diabetes and insulin resistance. A large number of AMPK activators have been employed with promising results in diabetic animal models and these encouraging results have provided the rationale for the development of new pharmacological (e.g., A-769662) but also nutritional (e.g., polyphenols) AMPK activators. AMPK activation in the liver and skeletal muscle entails metabolic changes that are beneficial for the diabetic patients with inhibition of HGP and stimulation of glucose uptake in skeletal muscle which help to maintain glycemia. However, some of the effects of AMPK activation in other organs or tissues should be carefully evaluated. The widespread cellular functions of AMPK make its selective targeting in therapeutics a difficult one, with simultaneous advantageous and deleterious consequences being possible. Thus, care should be taken that other metabolic effects due to AMPK activation could be detrimental for diabetic patients. One of the major caveats in the use of AMPK activators is their possible role in the regulation of food intake. Stimulation of AMPK expressed in specific nuclei of the hypothalamus has been shown to increase food intake ( ). Thus, the ideal AMPK activators will be administrated by the oral route, activate AMPK at low concentration and be 174 effective in specific target organs, such as the liver and skeletal muscle but not the hypothalamus, and will also have minimal off-targets.
An emerging concept is the use of tissue-specific pharmacological activation of AMPK that could be achieved through isoform-specific inserm-00367501, version 1 -11 Mar 2009 9 15 activation of AMPK. Interestingly, the small AMPK activator A-769662 is mainly targeted to the liver ( ) and treatment of animal 175 models with this compound recapitulates many of the effects expected for a specific hepatic AMPK activation ( ). Similarly, it appears 102 that the major effect of intravenous AICAR infusion in type 2 diabetic patients is restricted to the liver with inhibition of hepatic glucose output and decreased blood glucose levels ( ). Curiously, AMPK activation is not evident in muscle biopsies from healthy volunteers ( 142 ) or diabetic patients ( ) in response to AICAR infusion. These human data raise the question about the effective dose in producing 176 142 a detectable AMPK activation in skeletal muscle and the benefit in term of glucoregulation in diabetic patients.
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